Alembic Pharmaceuticals Other Announcement

PartnershipAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Partnership

Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.

From

DifGen Pharmaceuticals

Execution

Initial launches from FY28

Earnings Call

Alembic Pharmaceuticals Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).

Results Update

Alembic Pharmaceuticals Results Update

Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.

Value

₹2,603 Cr

Financial ResultsAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.2 Cr, Up 81.5% YoY

Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.

Key figure

Net profit ₹335.2 Cr · +81.5% YoY

Board Meeting Date

Alembic Pharmaceuticals Board Meeting Date

Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.

Regulatory ApprovalAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.

Other AnnouncementAmwill Health Care Ltd 544353

Amwill Health Care Other Announcement

Amwill Health Care committed ₹3 Crore to Nippon India Credit Opportunities AIF Scheme II. The investment, funded from internal accruals, is drawn down in tranches.

Value

₹3.00 Cr

Other AnnouncementKenvi Jewels Ltd KENVI

Kenvi Jewels Other Announcement

Kenvi Jewels informs BSE that its RTA, KFIN Technologies, will relocate its corporate office from 1 December 2026, with the registered office unchanged. The RTA appointment terms are unaffected, and shareholders should send correspondence to the new address.

Other AnnouncementAWL Agri Business Ltd AWL

AWL Agri Business Other Announcement

AWL Agri Business filed its quarterly shareholding pattern for the quarter ended 30 September 2026. The filing is routine regulatory disclosure with no transaction.

Other AnnouncementSashwat Technocrats Ltd SASHWAT

Sashwat Technocrats Other Announcement

Sashwat Technocrats informed BSE the escrow payment mechanism is not applicable to it. This is a routine compliance clarification with no financial impact.

Other AnnouncementVivid Mercantile Ltd 542046

Vivid Mercantile Other Announcement

Vivid Mercantile notified that its RTA, KFin Technologies, is relocating its corporate office from 1 December 2026. The registered office and the RTA appointment remain unchanged.

Other AnnouncementShyam Metalics and Energy Ltd SHYAMMETL

Shyam Metalics and Energy Other Announcement

Shyam Metalics intimated that its RTA, KFin Technologies, is shifting its corporate office and correspondence address effective 1 December 2026. The registered office of KFin remains unchanged.